Your browser doesn't support javascript.
loading
An Overview and Interpretation of Important Clinical Studies 
on Non-small Cell Lung Cancer in 2021 / 中国肺癌杂志
Chinese Journal of Lung Cancer ; (12): 295-302, 2022.
Article in Chinese | WPRIM | ID: wpr-928812
ABSTRACT
Though the coronavirus disease is still raging in 2021, clinical research on non-small cell lung cancer (NSCLC) did not stop. However, benefiting from advances in lung cancer treatment modality, NSCLC patients have experienced significant improvements in overall survival and quality of life. Currently, research advances on targeted therapy and immunotherapy have together transformed the status of postoperative adjuvant therapy and established a new standard treatment modality for resectable NSCLC. There are equally important research advances in locally advanced and advanced NSCLC, including new treatment modalities, new therapeutic agents, etc., all of which bringing more options for clinical treatment. These therapies will bring changes to NSCLC and will gradually lead to the chronicity of lung cancer in the foreseeable future. Therefore, this paper reviews important studies that will change clinical practice in NSCLC treatment and noteworthy research advances in 2021.
.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Quality of Life / Combined Modality Therapy / Carcinoma, Non-Small-Cell Lung / Immunotherapy / Lung Neoplasms Limits: Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2022 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Quality of Life / Combined Modality Therapy / Carcinoma, Non-Small-Cell Lung / Immunotherapy / Lung Neoplasms Limits: Humans Language: Chinese Journal: Chinese Journal of Lung Cancer Year: 2022 Type: Article